Trending Topic

3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
9 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The use of immune checkpoint inhibitors (ICIs) in treating cancer has greatly improved survival outcomes, particularly in patients with advanced disease for whom successful treatment options have previously been limited. For example, in patients with metastatic melanoma, the median survival time has improved from just 6 months to approximately 6 years with the use of […]

Amy S. Paller, Dermatology Meeting News: Advances in the Treatment of Atopic Dermatitis in Children

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 15th 2021

Following the AAD VMX meeting we caught up with Prof. Amy S. Paller (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss some of the presentations and recent advances being made in the treatment of children with atopic dermatitis.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.  

Disclosures: Prof. Amy Paller has acted as a consultant with honorarium for AbbVie, Abeona, Alcimed, Almirall, Amagma, Anaptysbio, Arena, Azitra, BiomX, Boehringer Ingelheim, Castle Biosciences, Catawba, Dermira, Eli Lilly, Exicure, Forte, Galderma, Kamari, Leo, Lifemax, NAOS, Novartis, Pfizer, Phoenix, Pierre Fabre, Sanofi/Genzyme, Seanergy, Trifecta and UCB; and an investigator (to institution) for AbbVie, Eli Lilly, Janssen, Regeneron, Incyte and UCB.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.

Filmed in coverage of the AAD VMX 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup